Oral Oncology
Volume 46, Issue 3 , Pages 195-199 , March 2010

Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland

  • Nazmiye Dincer

      Affiliations

    • Hacettepe University, Faculty of Medicine, Department of Pathology, Ankara, Turkey
    • Corresponding Author InformationCorresponding author. Address: Department of Pathology, Hacettepe University, Faculty of Medicine, Sihhiye, Ankara 06100, Turkey. Tel.: +90 532 618 35 60; fax: +90 312 312 69 55.
    • ,
  • Gaye Güler Tezel

      Affiliations

    • Hacettepe University, Faculty of Medicine, Department of Pathology, Ankara, Turkey
    • ,
  • Arzu Sungur

      Affiliations

    • Hacettepe University, Faculty of Medicine, Department of Pathology, Ankara, Turkey
    • ,
  • Cigdem Himmetoglu

      Affiliations

    • Hacettepe University, Faculty of Medicine, Department of Pathology, Ankara, Turkey
    • ,
  • Kay Huebner

      Affiliations

    • Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    • ,
  • Gülnur Güler

      Affiliations

    • Hacettepe University, Faculty of Medicine, Department of Pathology, Ankara, Turkey

Received 6 October 2009 ,Revised 7 December 2009 ,Accepted 8 December 2009.

References 

  1. Lopes MA, Kowalski LP, da Cunha Santos G, Paes de Almeida O. A clinicopathologic study of 196 intraoral minor salivary gland tumours. J Oral Pathol Med. 1999;28(6):264–267
  2. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg. 1974;128(4):512–520
  3. Monoo K, Sageshima M, Ito E, Nishihira S, Ishikawa K. Histopathological grading and clinical features of patients with mucoepidermoid carcinoma of the salivary glands. Nippon Jibiinkoka Gakkai Kaiho. 2003;106(3):192–198
  4. Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science. 1991;254(5035):1153–1160
  5. Huebner K, Garrison PN, Barnes LD, Croce CM. The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet. 1998;32:7–31
  6. Iliopoulos D, Guler G, Han SY, Druck T, Ottey M, McCorkell KA, et al. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett. 2006;232(1):27–36
  7. Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA. 2001;98(20):11417–11422
  8. Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, et al. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer. 2009;115(4):899–908
  9. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, et al. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int. 2005;55(8):471–478
  10. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. 1997;57(23):5207–5212
  11. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, et al. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res. 2000;60(5):1177–1182
  12. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, et al. Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res. 2000;6(9):3505–3510
  13. Huebner K, Hadaczek P, Siprashvili Z, Druck T, Croce CM. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim Biophys Acta. 1997;1332(3):M65–M70
  14. Huebner K, Druck T, Siprashvili Z, Croce CM, Kovatich A, McCue PA. The role of deletions at the FRA3B/FHIT locus in carcinogenesis. Recent Results Cancer Res. 1998;154:200–215
  15. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5′″-P1, P3-triphosphate hydrolase. Biochemistry. 1996;35(36):11529–11535
  16. Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, Rugge M, et al. Loss of FHIT expression in gastric carcinoma. Cancer Res. 1998;58(20):4708–4714
  17. Noguchi T, Muller W, Wirtz HC, Willers R, Gabbert HE. FHIT gene in gastric cancer: association with tumour progression and prognosis. J Pathol. 1999;188(4):378–381
  18. Hadaczek P, Debniak T, Kurzawski G, Jakubowska A, Huzarski T, Huebner K, et al. Fhit protein expression in hereditary and sporadic colorectal cancers. Pol J Pathol. 2001;52(3):125–132
  19. Lee SH. Aberrant FHIT transcripts in human colorectal cancers. Res Commun Mol Pathol Pharmacol. 2005;117–118:153–165
  20. Zanesi N, Mancini R, Sevignani C, Vecchione A, Kaou M, Valtieri M, et al. Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. Cancer Res. 2005;65(15):6576–6582
  21. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA. 2001;98(18):10250–10255
  22. Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA. 2001;98(6):3346–3351
  23. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res. 1999;59(16):3866–3869
  24. Michael D, Beer DG, Wilke CW, Miller DE, Glover TW. Frequent deletions of FHIT and FRA3B in Barrett’s metaplasia and esophageal adenocarcinomas. Oncogene. 1997;15(14):1653–1659
  25. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, et al. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res. 1999;59(20):5270–5274
  26. Yuge T, Nibu K, Kondo K, Shibahara J, Tayama N, Sugasawa M. Loss of FHIT expression in squamous cell carcinoma and premalignant lesions of the larynx. Ann Otol Rhinol Laryngol. 2005;114(2):127–131
  27. Ozaki K, Enomoto T, Yoshino K, Fujita M, Buzard GS, Kawano K, et al. Impaired FHIT expression characterizes serous ovarian carcinoma. Br J Cancer. 2001;85(2):247–254
  28. Man S, Ellis IO, Sibbering M, Blamey RW, Brook JD. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res. 1996;56(23):5484–5489
  29. Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T, et al. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res. 2003;1(13):940–947
  30. Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE, et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat. 2005;89(2):99–105
  31. Nakayama S, Semba S, Maeda N, Aqeilan RI, Huebner K, Yokozaki H. Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci. 2008;99(7):1370–1376
  32. Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H, et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res. 2004;10(7):2459–2465
  33. Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene. 2005;24(9):1625–1633
  34. Ludes-Meyers JH, Bednarek AK, Popescu NC, Bedford M, Aldaz CM. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res. 2003;100(1–4):101–110
  35. Nunez MI, Ludes-Meyers J, Aldaz CM. WWOX protein expression in normal human tissues. J Mol Histol. 2006;37(3–4):115–125
  36. Lewandowska U, Zelazowski M, Seta K, Byczewska M, Pluciennik E, Bednarek AK. WWOX, the tumour suppressor gene affected in multiple cancers. J Physiol Pharmacol. 2009;60(Suppl. 1):47–56
  37. Chang NS, Doherty J, Ensign A, Schultz L, Hsu LJ, Hong Q. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem. 2005;280(52):43100–43108
  38. Qin HR, Iliopoulos D, Nakamura T, Costinean S, Volinia S, Druck T, et al. Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. Mol Cancer Res. 2007;5(9):957–965
  39. Qin HR, Iliopoulos D, Semba S, Fabbri M, Druck T, Volinia S, et al. A role for the WWOX gene in prostate cancer. Cancer Res. 2006;66(13):6477–6481
  40. Bloomston M, Kneile J, Butterfield M, Dillhoff M, Muscarella P, Ellison EC, et al. Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features. Ann Surg Oncol. 2009;16(8):2331–2338
  41. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer. 2004;100(8):1605–1614
  42. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lövgren K, et al. The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10(3):R53
  43. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116–4124
  44. Miyoshi Y, Murase K, Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol. 2008;13(5):395–400
  45. Ishii H, Wang Y, Huebner K. A Fhit-ing role in the DNA damage checkpoint response. Cell Cycle. 2007;6(9):1044–1048
  46. Cantor JP, Iliopoulos D, Rao AS, Druck T, Semba S, Han SY, et al. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer. 2007;120(1):24–31

PII: S1368-8375(09)00999-3

doi: 10.1016/j.oraloncology.2009.12.003

Oral Oncology
Volume 46, Issue 3 , Pages 195-199 , March 2010

Article Tools

* Image Usage & Resolution